时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
However, these physicochemical conditions alone do not determine the final cell-death phenotype (71).The transition from ROS accumulation to ferroptosis is mainly determined by whether oxidative stress can overcome lipid-peroxide defense systems.；Such synergistic interactions have become a major objective in the development of next-generation magnetic nanoplatforms.
方法
Conventional modalities such as surgery, chemotherapy, radiotherapy, and immunotherapy have improved survival for many patients, yet their effectiveness is often limited by systemic toxicity, incomplete tumor selectivity, relapse, and the adaptive nature of the tumor microenvironment.；This integrated sequence links nanoparticle design, ROS-generation mechanisms, engineering approaches, and therapeutic combinations within a single framework.；In addition, many systems still depend on favorable intratumoral conditions that are not uniform across patients or tumor types.
核心结论
These findings support the idea that MNPs do not act through a single mechanism, but rather through a network of interrelated oxidative and metabolic disruptions that can be therapeutically leveraged (15, 16).Recent studies have also shown that MNPs can improve treatment response when combined with other therapeutic platforms.；Ebadi et al. demonstrated that surface-engineered Fe3O4 nanoparticles possessed spherical morphology and relatively uniform particle dispersion according to TEM and FESEM observations, while XRD analysis confirmed the preservation of the crystalline magnetite structure following functionalization (Figures 2a–c) (33).；Panel c displays an X-ray diffraction pattern with multiple crystalline peaks, and panel d shows two curves on a graph comparing intensity versus nanoparticle diameter in nanometers on a logarithmic scale.Taken together, the therapeutic potential of MNPs is determined by more than magnetism alone.
局限
These limitations have encouraged the development of nanomedicine-based strategies designed to improve tumor accumulation, therapeutic precision, and multimodal treatment performance (2, 3).Within this context, reactive oxygen species (ROS) have emerged as a particularly attractive therapeutic target.；Many advanced magnetic nanoplatforms are therefore designed not only to increase ROS generation but also to deplete intracellular antioxidants, further disrupting redox homeostasis and amplifying oxidative injury (23, 43).Despite these advantages, the TME can also impose limitations on ROS-mediated therapy.；However, excessive size reduction can compromise magnetic properties, alter biodistribution patterns, and accelerate systemic clearance, highlighting the need for careful size optimization (49).Morphology and crystal structure also contribute significantly to catalytic behavior.
对本项目的价值
中高价值：属「线粒体质量控制与氧化应激」方向；线粒体功能与氧化应激栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.1/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 135,893 字符，题名指纹 0.93，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：肿瘤氧化还原界面上的磁性纳米平台：从催化 ROS 放大到铁死亡与多模态癌症治疗
- 英文标题：Magnetic nanoplatforms at the tumor redox interface: from catalytic ROS amplification to ferroptosis and multimodal cancer therapy.
- 期刊与标识：Frontiers in oncology · PMID 42978988 · DOI 10.3389/fonc.2026.2001431 · PMC PMC13728875